ReviewCritical care (London, England)2020
Update of the treatment of nosocomial pneumonia in the ICU.
Review in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 3 syntheses or guidelines pooled it, 241 citations in OpenAlex.
- Continuous or extended vs intermittent infusions of beta-lactam antibiotics in ICU patients with pneumonia: a systematic review and meta-analysis of randomized controlled trials.Antimicrobial agents and chemotherapy · 2025Pooled it
- Inhaled antibiotics for treating pneumonia in invasively ventilated patients in intensive care unit: a meta-analysis of randomized clinical trials with trial sequential analysis.Critical care (London, England) · 2024Pooled it
- Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.Antimicrobial agents and chemotherapy · 2026Trial
- Traditional Chinese Medicine treatment with syndrome differentiation for patients with severe community-acquired pneumonia: a multicenter, randomized, placebo-controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Trial
- Fibrinolysis Resistance After Injury Is a Risk Factor for a Hospital-Acquired Pneumonia-Like Disease Pattern.Surgical infections · 2024Trial
- Short-term exposure to ambient fine particulate pollution aggravates ventilator-associated pneumonia in pediatric intensive care patients undergoing cardiovascular surgeries.Environmental health : a global access science source · 2023Trial
- Bronchopulmonary disposition of IV cefepime/taniborbactam (2-0.5 g) administered over 2 h in healthy adult subjects.The Journal of antimicrobial chemotherapy · 2023Trial
- Trial
- Multi-targeted biomimetic CeO₂-based nanoplatform for sepsis therapy via mitochondrial homeostasis.International journal of pharmaceutics: X · 2026Article
- Large language models for pneumonia detection in radiology reports via text analysis.PLOS digital health · 2026Article
- Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia in the intensive care unit.Journal of thoracic disease · 2026Article
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Oral findings in intensive care unit patients.Medicina oral, patologia oral y cirugia bucal · 2026Article
- Surveillance of temporal trends and antimicrobial resistance in nosocomial respiratory pathogens, Switzerland, 2007 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Evaluation of Antibiotic Use in Patients Admitted to a Hungarian Intensive Care Unit with Pneumonia and Sepsis: Retrospective Observational Before-After Study.Antibiotics (Basel, Switzerland) · 2026Article
- Association between albumin-corrected anion gap and 28-day mortality in critically ill patients with pneumonia in the intensive care unit: evidence from the medical information mart for intensive care IV database.BMC pulmonary medicine · 2026Observational
- Efficacy of cefiderocol in murine models of ventilator-associated pneumonia caused by carbapenem-resistant non-fermenting Gram-negative bacilli, with pharmacokinetic evaluation.Microbiology spectrum · 2026Article
- Real-world experience using multiplex polymerase chain reaction in intensive care unit patients with hospital-acquired and ventilator-associated pneumonia in South Korea.Acute and critical care · 2026Article
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 12 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In accordance with the recommendations of, amongst others, the Surviving Sepsis Campaign and the recently published European treatment guidelines for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), in the event of a patient with such infections, empirical antibiotic treatment must be appropriate and administered as early as possible. The aim of this manuscript is to update treatment protocols by reviewing recently published studies on the treatment of nosocomial pneumonia in the critically ill patients that require invasive respiratory support and patients with HAP from hospital wards that require invasive mechanical ventilation. An interdisciplinary group of experts, comprising specialists in anaesthesia and resuscitation and in intensive care medicine, updated the epidemiology and antimicrobial resistance and established clinical management priorities based on patients' risk factors. Implementation of rapid diagnostic microbiological techniques available and the new antibiotics recently added to the therapeutic arsenal has been reviewed and updated. After analysis of the categories outlined, some recommendations were suggested, and an algorithm to update empirical and targeted treatment in critically ill patients has also been designed. These aspects are key to improve VAP outcomes because of the severity of patients and possible acquisition of multidrug-resistant organisms (MDROs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.